Shares of Intercept Pharmaceuticals ICPT rose 2.9% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 37.84% year over year to ($1.61), which beat the estimate of ($1.93).
Revenue of $79,521,000 higher by 28.36% from the same period last year, which beat the estimate of $78,630,000.
Looking Ahead
Intercept Pharmaceuticals hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $310,000,000 and $320,000,000.
Conference Call Details
Date: Nov 09, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/b3wvunam
Price Action
52-week high: $125.00
Company's 52-week low was at $27.02
Price action over last quarter: down 44.92%
Company Overview
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.